One group received citalopram (up to 60 mg/day) plus vitamin C (up to 1,000 mg/day). The other group received citalopram plus placebo.

What we find is that think of it this way. Let’s say, the reference range of vitamin C in the bloodstream is one milligram per deciliter. After a 15,000, a 15-gram IBC infusion and we typically, do measure people after we give them an infusion, it’s about 100 milligrams per deciliter. It’s 100 times what you would normally have in your blood. Now, you can take as much oral vitamin C as you can and you might get it up from one to maybe three, maybe four, maybe five if you’ve already been taking vitamin C for a long time but to get beyond that is almost impossible.

Now, there are cases where people have taken, they’ve built themselves up to 50, 60,000 milligrams of oral vitamin C a day over months and years and they can achieve a higher blood level in the 20s, maybe the 30s. What we’re shooting for with cancer patients is for 400 milligrams per deciliter.

I think the concept of antioxidants has been misunderstood. What Dr. Tom Levy and I have introduced at our most recent conference is this concept of redox medicine that everything in nature is redox. Dave Asprey:                     Yes. Explain redox for our listeners. This is also in headstrong. Just like define that. It’s so important. You guys will have to hear this. Ron Hunninghake:           Yeah. Well, life is redox. There’s oxidation, there is reduction. Oxidation is when molecules lose electrons and it causes dysfunction of some sort. Reduction is when from some source, such as vitamin C or good quality food, you are able to get electrons back in order to stabilize the molecule and to stabilize the structures that it’s working within.

There are some other doctors that have looked at depriving cancer patients of all vitamin C for periods of time and then hitting them really hard with high doses of vitamin C as a possible way of inducing apoptosis in cancer cells. There’s a lot of research in this area and it’s not like it’s all worked out now. It’s more like we are in the early stages of flight and we need research is what we really need and unfortunately, it’s hard to come by at the funding for this particular area.